NCCN Guidelines® Insights - Melanoma: Cutaneous, Version 2.2021
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Systemic Therapy Considerations (added in v2.2020), and Brain Metastases Management (added in v3.2020). The v1.2021 update included additional modiﬁcations of these sections and notable revisions to Principles of: Pathology, Surgical Margins for Wide Excision of Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic Lymph Node Dissection, and Radiation Therapy. These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Melanoma: Cutaneous
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma: Cutaneous
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kaneﬁeld; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
Susan M. Swetter, MD, Panel Chair, has disclosed no relevant ﬁnancial relationships.
John A. Thompson, MD, Panel Vice Chair, has disclosed receiving consulting fees from AVEO Pharmaceuticals, Inc., Calithera, Neoleukin, Regeneron Pharmaceuticals, Inc., and sanoﬁ-aventis US; and serving as a scientiﬁc advisor for and receiving stock options for Alpine Immune Sciences.
Mark R. Albertini, MD, Panel Member, has disclosed receiving grant/research support from Bristol Myers Squibb, Apeiron Biologics, Array BioPharma, and Merck Sharpe & Dohme.
Genevieve Boland, MD, PhD, Panel Member, has disclosed receiving grant/research support from Olink Proteomics and Palleon Pharmaceuticals, and serving as a scientiﬁc advisor for Nektar Therapeutics.
Alison Durham, MD, Panel Member, has disclosed no relevant ﬁnancial relationships.
Ryan C. Fields, MD, Panel Member, has disclosed no relevant ﬁnancial relationships.
Brian Gastman, MD, Panel Member, has disclosed receiving grant/research support from Merck & Co., Inc., Alkermes, IntillBio, and NeoImmune Tech; serving on the product/speakers bureau and receiving equity interest/stock options in Castle Biosciences; and receiving consulting fees from Castle Biosciences, Iovance, and Quest Imaging.
Douglas Johnson, MD, Panel Member, has disclosed serving as a scientiﬁc advisor for Bristol Myers Squibb Company, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation; receiving grant/research support from Bristol Myers Squibb Company and Incyte Corporation; and receiving consulting fees from Janssen Pharmaceutica Products, LP, Catalyst Biopharma, Iovance, and Oncosec.
Giorgos Karakousis, MD, Panel Member, has disclosed receiving grant/research support from Merck & Co., Inc.
Kim Margolin, MD, Panel Member, has disclosed receiving consulting fees from ImaginAb, Oncosec, Werewolf, Tentarix, Xilio, and Mizuno; and serving as a scientiﬁc advisor for Pﬁzer and Checkmate Pharmaceuticals.
Patrick A. Ott, MD, PhD, Panel Member, has disclosed receiving grant/research support from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb Company, Genentech, Inc., GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Oncorus, Xencor, and Pﬁzer Inc.; and serving as a scientiﬁc advisor for Merck & Co., Inc.
Merrick I. Ross, MD, Panel Member, has disclosed receiving consulting fees and honoraria from Amgen Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation; serving as a scientiﬁc advisor for Amgen Inc. and Merck & Co., Inc.; and serving on the product/speakers bureau for Merck & Co., Inc.
April K. Salama, MD, Panel Member, has disclosed serving as a scientiﬁc advisor for Novartis Pharmaceuticals Corporation, Iovance, Pﬁzer Inc., and Regeneron Pharmaceuticals, Inc.
Rohit Sharma, MD, Panel Member, has disclosed no relevant ﬁnancial relationships.
Jeffrey Sosman, MD, Panel Member, has disclosed receiving consulting fees from Genentech, Inc., and Nektar Therapeutics; and serving as a scientiﬁc advisor for and receiving honoraria from Bristol Myers Squibb.
Nicole R. McMillian, MS, CHES, Guidelines Coordinator, NCCN, has disclosed no relevant ﬁnancial relationships.
Anita M. Engh, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed no relevant ﬁnancial relationships.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-21-007-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 10, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation